Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

BILIX

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

South Korea, AsiaBiotech & life sciences, Drug for acute kidney injuryKorea – Gyeongsan 2026
Stage
Series ANo documented AI
Product
PilotPilots / LOIs
Funding raised
$13.3Mdisclosed
Founded
20188 years ago
Founders
2Kim, Jon
Global score
4.5Grade DRank 63 of 151

Overview

Bilix (빌릭스), a Korean biotech founded in 2018 (spin-off from Prof. Jon Sang-yong's lab at KAIST), develops PEGylated bilirubin drugs; lead candidate BX-001N aims to prevent acute kidney injury during cardiac surgery and organ transplantation.

Traction

Pilots / LOIs

BX-001N. phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.

Market

Acute kidney injury treatment

Acute kidney injury after cardiac surgery is frequent and costly, and no preventive drug is widely established, so a positive phase 2 would be very valuable. Hospitals would administer the drug peri-operatively, but value is realised through licensing to pharma after phase 2. Buyers today are pharma business-development teams and, eventually, hospital formularies and payers. Clinical risk is binary.

Addressable market

2025
$2B
2030
$2.9B
+8.3% a year

Acute kidney injury treatment: $1.96bn in 2025, +8.3%/year, $2.92bn in 2030 (Coherent Market Insights; up to $7.2bn with a broad scope).

Customers

Pharma licensing partners; eventually cardiac-surgery and transplant centres

Who signs the cheque

Pharma BD/licensing teams; hospital formulary committees and payers (later)

Geographies

  • South Korea
  • Australia
  • United States (planned FDA phase 2b)

Drivers

  • High incidence and cost of post-surgical AKI
  • Lack of approved preventive therapies (general clinical context)
  • Korean public funding (KDDF) de-risking trials

Headwinds

  • Phase 2 failure risk
  • Large capital needs for phase 2b/3
  • Long time to revenue

The acute kidney injury treatment market is estimated at $1.96bn in 2025 (+8.3%/year, $3.4bn in 2032) according to Coherent Market Insights (up to $7.2bn with a broad scope).

Scalability 5/10. Potential global drug, but phase 2 under way and approvals country by country.

Market source: giiresearch.com

Technology

Category

Therapeutics – nanomedicine

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

PEGylated bilirubin nanoparticles with antioxidant and immunomodulatory activity protect organs against ischemia-reperfusion injury. Lead candidate BX-001N targets cardiac-surgery-associated AKI.

Moat

Strong if efficacy is shown: KAIST platform IP, phase 1 data and clinical know-how.

Differentiation

Uses an endogenous antioxidant (bilirubin) made drug-like by PEGylation, addressing multiple inflammatory injury pathways.

Integration points

  • Cardiac-surgery and transplant trial networks
  • Real-world data providers for trial design
  • Pharma licensing partners
  • CROs

Depends on

  • Phase 2a/2b efficacy
  • CMC/scale-up
  • FDA IND for phase 2b

Use of AI

No use of AI mentioned

Product in detail

PEGylated bilirubin nanomedicine platform (antioxidant and immunomodulatory activity); BX-001N against cardiac surgery-associated acute kidney injury (CSA-AKI); other inflammatory indications (ischemia-reperfusion).

Business

Model
Drug development with licensing/partnering after clinical proof of concept.
Revenue logic
Upfront and milestone payments plus royalties from a pharma licensee.
Go-to-market
Out-licensing; supported by KDDF and Korean investors.

Next milestones

  1. Positive phase 2a readout
  2. FDA IND clearance for phase 2b
  3. Regional or global licensing deal

Key risks

  • Clinical failure
  • Financing needs
  • Competitive AKI pipelines

Opportunities

4 found in the network

Concrete moves for BILIX inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Customers 1
  • Investors 2
  • Peers 1

Customers1

Who could buy, or sell through

Buy Latin American real-world data to design phase 2b/3 and select sites

Phase 2b/3 design needs AKI incidence after cardiac surgery, baseline risk and site volumes. Cromodata's hospital network in five Latin American countries can supply de-identified cohorts and identify high-volume sites. Bilix gets cheaper trial design and new geographies; Cromodata gets a named pharma-type buyer.

30%confidence

Evidence from the records

  • “Marketplace in operation: claimed network of 47 to 84+ healthcare facilities in 5 countries (Argentina, Uruguay, Mexico, Dominican Rep., Brazil); no data buyer publicly named.”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
If it works
A feasibility dataset and shortlisted LatAm sites for later trials.
First step
Send Cromodata a cohort definition (cardiac surgery, creatinine follow-up) and request a feasibility count.

Investors2

A fund whose thesis fits

Approach Sands Capital for the Series C, via PolyJoule

Sands Capital invests at Series A and later in biotech and medtech globally, matching Bilix's late-private stage. It is reported as an investor in PolyJoule in the network.

20%confidence

Evidence from the records

  • “Sands Capital Ventures and others (according to aggregators)”
  • “High risk: phase 2 clinical risk and large funding needs despite US$13M raised.”
If it works
A global growth-stage biotech investor for the post-phase-2a round.
First step
Ask PolyJoule's CEO for an intro to Sands Capital's life-science team.

Pitch EFung Capital, Pleryon's biotech investor

EFung invests at Series A and later in biotech in China and globally and backed Pleryon Therapeutics in the network; an Asian investor fits a Korean asset seeking regional licensing.

20%confidence

Evidence from the records

  • “EFung Capital (cited by CB Insights and Caplight); other historical investors: Zero2IPO, Kaitai Capital, Lapam Capital, HKUST R&D Corporation”
  • “Successful phase 1”
If it works
Capital plus access to Chinese licensing partners.
First step
Ask Pleryon's team for an intro to EFung Capital.

Peers1

Founders solving the same problem elsewhere

Exchange on polymer-drug CMC and Asian licensing

Both companies develop polymer-based therapeutics at Series A in Asia. Sharing CMC suppliers, regulatory strategy and licensing contacts reduces cost and time for both.

20%confidence

Evidence from the records

  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
  • “PEGylated bilirubin nanomedicine platform (antioxidant and immunomodulatory activity)”
If it works
Shared vendor lists and licensing introductions.
First step
Arrange a CEO call during the Grand Finale.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Shenzhen life-science investor (since 2012) backing drug developers with phase 2/3 assets and device makers; backed Pleryon Therapeutics.

Acute-kidney-injury drug with phase 1 done and phase 2a under way, at Series A: a clinical-stage asset approaching EFung's phase 2 sweet spot.

55%confidence

Evidence from the records

  • “drug developers with phase 2/3 assets”
  • “Drug for acute kidney injury”
  • “phase 2a under way in Korea”
Intro path
Pleryon Therapeutics (EFung portfolio)
First step
Send phase 1 data and the phase 2a design to EFung's CSO.

Life-sciences and venture arm of Sands Capital ($54B+ AUM); Pulse strategy ($1.3B) backs therapeutics, diagnostics, devices and tools.

KAIST spin-off with acute-kidney-injury drug BX-001N past phase 1 and in phase 2a: a clinical-stage therapeutic at Series A, the Pulse sweet spot.

50%confidence

Evidence from the records

  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea”
  • “Series A”
Intro path
Co-investors include Solbrain Holdings and WeVentures.
First step
Send BILIX's phase 1 data package to the Pulse team.

Chinese VC with no profile in our data; investor in Pleryon Therapeutics' Pre-A and Series A.

Korean AKI drug at Series A — therapeutic at the same stage.

25%confidence

Evidence from the records

  • “Series A”
  • “Drug for acute kidney injury”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Kaitai Capital).
First step
Qualify via Pleryon.

Seoul National University's technology holding company, backing SNU-linked Korean startups such as SLZ and JJ&Companies.

KAIST spin-off drug for acute kidney injury in phase 2a: Korean university deep tech, but KAIST not SNU, and already at Series A.

20%confidence

Evidence from the records

  • “spin-off from Prof. Jon Sang-yong's lab at KAIST”
  • “Series A”

Investor with no public profile in our data; its only known deal is an $8M pre-Series A extension in BioSapien.

Korean acute-kidney-injury drug at Series A — therapeutic with clinical milestones similar to BioSapien's profile.

20%confidence

Evidence from the records

  • “pre-Series A extension”
  • “Drug for acute kidney injury”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
Intro path
Founder-to-founder intro via BioSapien (network portfolio company of Globivest).
First step
Qualify Globivest via BioSapien first.

Beijing VC/PE services group (founded 2000 by Gavin Ni, HK-listed since 2020); historical investor in Pleryon Therapeutics' Pre-A and Series A.

Korean clinical-stage kidney drug at Series A: biotech like Pleryon, outside China.

20%confidence

Evidence from the records

  • “Drug for acute kidney injury”
  • “Series A”
First step
Low priority without a China angle.

Chinese VC with no profile in our data; investor in Pleryon Therapeutics' Pre-A and Series A.

Korean AKI drug at Series A.

20%confidence

Evidence from the records

  • “Series A”
  • “Drug for acute kidney injury”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
Intro path
Founder-to-founder intro via Pleryon Therapeutics (network portfolio company of Lapam Capital).
First step
Qualify via Pleryon.

Holding that invested in BioSapien's US$5.5M pre-Series A (oncology drug delivery); profile is undocumented.

Korean acute-kidney-injury drug in phase 2a: clinical-stage biotech like BioSapien.

20%confidence

Evidence from the records

  • “Drug for acute kidney injury”
  • “phase 2a under way in Korea”
Intro path
BioSapien (Dara portfolio)
First step
Ask BioSapien for an intro.

Seoul VC with no profile in our data; invested in JJ&Companies' 2022 pre-Series A in maritime AI.

Korean AKI drug — biotech.

15%confidence

Evidence from the records

  • “JJ&Companies”
  • “Drug for acute kidney injury”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
Intro path
Founder-to-founder intro via JJ&Companies (network portfolio company of NVC Partners).
First step
Low priority.

Investment analysis

4.5D

Grade D

Rank 63 of 151

Disruption7.0/10
Business model3.0/10
Market4.0/10
Risk(lower is better)7.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Serious clinical-stage biotech, but binary: speculative.

Disruption

7/10

PEGylated bilirubin against acute kidney injury: a new therapeutic approach.

Business model

3/10

Phase 1 completed and phase 2a under way, no revenue.

Market

4/10

TAM $1.96bn → base 4; scalability 5/10 (neutral); no international presence: no sales (trials in Australia and Korea) → 4/10.

Risk

7/10

Lower is better

High risk: phase 2 clinical risk and large funding needs despite US$13M raised.

Strengths

  • Successful phase 1
  • KAIST and industry founders

Risks

  • Risk of clinical failure
  • High capital requirements

Funding

$13.3M, disclosed
  1. 2018-2019

    seednot published

    DS Asset Management, Alpenroute Asset Management

  2. 2019-07

    pre-Series AKRW 2.5bn

    not published

  3. 2019-11-29

    strategic investmentKRW 2bn

    Estech Pharma (에스텍파마)

  4. 2021 (S1)

    Series AKRW 14bn

    DS Asset Management (follow-on), Magnine Investment, WeVentures, IBK (Industrial Bank of Korea), Genexis, Estech Pharma (follow-on), Solbrain Holdings

  5. non daté

    Series B (TheVC, not confirmed); KRW 10bn Series C in progress according to TheVCnot published

    not published

  6. 2026-07

    grantnot specified (KRW 12.4bn in public projects in H1 2026 according to the company)

    KDDF – Korea Drug Development Fund (phase 2a and FDA phase 2b IND for BX-001N)

  7. 2026-07-06

    prizeKRW 3M

    Startup World Cup Korea-Gyeongsan grand prize + Gyeongbuk Governor's Prize

Amount used in the study. Pre-Series A KRW 2.5bn + strategic KRW 2bn + Series A KRW 14bn + KRW 3M prize; KRW 12.4bn in claimed public projects as upper bound.

Note. ≥ KRW 18.5bn (~$13M) known up to 2021 (unquantified seed + KRW 2.5bn + 2bn + 14bn); TheVC mentions a Series B round and a KRW 10bn Series C in progress (not confirmed); KRW 12.4bn in public grants claimed in H1 2026

Funding history reconstructed (Biospectator 2019, IB Tomato 2021). A Series B targeted at KRW 30bn in 2022 is not publicly confirmed (TheVC shows it): stage set to at least Series A, possibly Series B. City "Gyeongsan" = competition venue (Yeungnam University), not the headquarters: reset to null (headquarters not found). Gyeongsan regional held on 6 July 2026.

Team

  • Kim Myung-rip (김명립)

    Co-founder & CEO

    Former manager at SK Telecom (in vitro diagnostics), Nanoentec and Eutilex (CTO/COO).

  • Jon Sang-yong (전상용)

    Co-founder

    Distinguished professor at KAIST; his team developed the PEGylated bilirubin platform.

Sources

Regional final
Korea – Gyeongsan 2026
Identification confidence
high
  1. 1venturesquare.net/en/1096875/
  2. 2venturesquare.net/1096872/
  3. 3biospectator.com/news/view/9024
  4. 4ibtomato.com/mobile/mView.aspx?no=5949&type=1
  5. 5clinicaltrials.gov/study/NCT07164833
  6. 6dailypharm.com/user/news/340142

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet